Laurus Labs Limited has outperformed the stock market and pharma sector, Pharma Sector is in flavour since the COVID-19 pandemic and pharma sector has outperformed all indices and in Pharma sector laurus Labs has outperformed the pharma sector by a big way.
Laurus labs limited share has given returns of 300% in last 3 months. Share is trading around Rs. 1260 per share which was trading at Rs. 450 levels around three months ago.
Business Model:-
•Mr. Satyanarayana Chava,
Founder & CEO of the Laurus Labs Limited
•Laurus Labs is having headquarters in Hyderabad and it is an Indian pharmaceutical
company. This company is involved in the research and development
of active pharmaceutical ingredients (API) for anti-retrovirals, hepatitis
C drugs,
oncology,
cardiovascular, anti-diabetics, anti-asthma, and gastroenterology.
This Pharma company is the world's largest third party API supplier for anti-retrovirals.
•During Covid-19 Pandemic In
March
2020, Laurus
Labs received USFDA approval to market hydroxychloroquine
sulfate tablets, which earlier are used in treatment by USA for COVID-19 treatment.
The company announced that it would supply
hydroxychloroquine
to its US partner Rising Pharma for clinical trials of preventive
treatment of COVID-19.
Financial results:-
From Financial you can see that how its profitability is getting improved quarter on quarter in 1 year profitability has been increase from Rs. 15 crores to Rs. 171 crores i.e. Jump of more than 10 times in profitability.
Also you can see that sales has been increased from Rs. 550 crores to Rs. 974 crores.
Shareholding:-
Comparative with Lupin and Aurobindo Pharma:-
For more details visit link as below:-
I Like to add one more important thing here, The Active Pharmaceutical Ingredients Market is expected to be around US$ 238.5 Billion by 2025 at a CAGR of 6% in the given forecast period.
ReplyDelete